Related Experiment Video
Updated: Dec 4, 2025

Author Spotlight: Exploring Microglial Interactions with Stress-Response Circuitry Using the Limited Bedding and Nesting Model
Published on: July 12, 2024
Early Life Stress- and Drug-Induced Histone Modifications Within the Ventral Tegmental Area
Ryan D Shepard1, Fereshteh S Nugent1
1Department of Pharmacology, Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Abstract:
Psychiatric illnesses are a major public health concern due to their prevalence and heterogeneity of symptom presentation resulting from a lack of efficacious treatments. Although dysregulated dopamine (DA) signaling has been observed in a myriad of psychiatric conditions, different pathophysiological mechanisms have been implicated which impede the development of adequate treatments that work across all patient populations. The ventral tegmental area (VTA), a major source of DA neurons in the brain reward pathway, has been shown to have altered activity that contributes to reward dysregulation in mental illnesses and drug addiction. It has now become better appreciated that epigenetic mechanisms contribute to VTA DA dysfunction, such as through histone modifications, which dynamically regulate transcription rates of critical genes important in synaptic plasticity underlying learning and memory. Here, we provide a focused review on differential histone modifications within the VTA observed in both humans and animal models, as well as their relevance to disease-based phenotypes, specifically focusing on epigenetic dysregulation of histones in the VTA associated with early life stress (ELS) and drugs of abuse. Locus- and cell-type-specific targeting of individual histone modifications at specific genes within the VTA presents novel therapeutic targets which can result in greater efficacy and better long-term health outcomes in susceptible individuals that are at increased risk for substance use and psychiatric disorders.
Insights
Epigenetic changes in the ventral tegmental area (VTA) impact dopamine signaling, contributing to psychiatric disorders. Targeting these histone modifications offers new therapeutic avenues for addiction and mental illness.
Area of Science:
- Neuroscience
- Psychiatry
- Epigenetics
Background:
- Psychiatric illnesses pose significant public health challenges due to varied symptoms and limited effective treatments.
- Dysregulated dopamine signaling is implicated across psychiatric conditions, yet underlying mechanisms remain complex.
- The ventral tegmental area (VTA) is crucial for reward pathways, and its altered activity contributes to mental illness and addiction.
Purpose of the Study:
- To review differential histone modifications in the VTA.
- To explore the relevance of these epigenetic changes to disease phenotypes.
- To focus on VTA histone dysregulation linked to early life stress and substance abuse.
Main Methods:
- Review of studies on histone modifications in the VTA.
- Analysis of human and animal models of psychiatric disorders.
- Focus on epigenetic mechanisms in VTA dopamine neuron dysfunction.
Main Results:
- Histone modifications in the VTA are implicated in psychiatric disorders.
- Early life stress and drug exposure induce specific epigenetic changes in the VTA.
- These modifications affect gene transcription related to synaptic plasticity.
Conclusions:
- Epigenetic dysregulation of histones in the VTA contributes to psychiatric conditions.
- Targeting specific histone modifications in the VTA offers potential therapeutic strategies.
- This approach may improve treatment efficacy and long-term outcomes for at-risk individuals.
Related Concept Videos
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Stress and Mental Health
Individuals with depression often experience challenges in both their personal and professional...
Drug Abuse and Addiction: Pharmacological Phenomena
Drugs Affecting Neurotransmitter Synthesis

